Gun H. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Endovascular Treatment of Intrahepatic Hepatic Artery Pseudoaneurysms: Safety and Efficacy According to Embolization Strategies.

Endovascular Treatment of Intrahepatic Hepatic Artery Pseudoaneurysms: Safety and Efficacy According to Embolization Strategies.

Journal: Radiology

Published: July 21, 2026

Efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma.

Efficacy and safety of boosted transarterial radioembolization in patients with chemoembolization-refractory hepatocellular carcinoma.

Journal: Acta radiologica (Stockholm, Sweden : 1987)

Published: July 14, 2026

Initial drug-eluting beads transarterial chemoembolization using hepaspheres in patients with large (≥5 cm) hepatocellular carcinoma.

Initial drug-eluting beads transarterial chemoembolization using hepaspheres in patients with large (≥5 cm) hepatocellular carcinoma.

Journal: European journal of radiology

Published: March 16, 2026

Transarterial Radioembolization Versus Transarterial Chemoembolization in Elderly Patients (≥75 Years) With Hepatocellular Carcinoma: A Propensity Score-Matched Comparison.

Transarterial Radioembolization Versus Transarterial Chemoembolization in Elderly Patients (≥75 Years) With Hepatocellular Carcinoma: A Propensity Score-Matched Comparison.

Journal: Korean journal of radiology

Published: January 27, 2026

Lipiodol-Based Balloon-Occluded Transcatheter Arterial Chemoembolization Can Be a Curative Treatment Option for Hepatocellular Carcinoma.

Lipiodol-Based Balloon-Occluded Transcatheter Arterial Chemoembolization Can Be a Curative Treatment Option for Hepatocellular Carcinoma.

Journal: Journal of vascular and interventional radiology : JVIR

Published: January 13, 2026

Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: An Inverse Probability of Treatment Weighted Analysis.

Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: An Inverse Probability of Treatment Weighted Analysis.

Journal: Cancers

Published: November 20, 2025

Effectiveness and Safety of Transarterial Radioembolization Following Inferior Phrenic Artery Glue Embolization for Flow Redistribution in Hepatocellular Carcinoma.

Effectiveness and Safety of Transarterial Radioembolization Following Inferior Phrenic Artery Glue Embolization for Flow Redistribution in Hepatocellular Carcinoma.

Journal: Journal of vascular and interventional radiology : JVIR

Published: November 05, 2025

Nickel-Catalyzed Twofold Conjunctive Coupling via Philicity-Alternating Radical Relay.

Nickel-Catalyzed Twofold Conjunctive Coupling via Philicity-Alternating Radical Relay.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: October 27, 2025

Plug-Assisted Retrograde Transvenous Obliteration for Gastric Varices: Long-Term Outcomes of Primary and Secondary Prophylaxis.

Plug-Assisted Retrograde Transvenous Obliteration for Gastric Varices: Long-Term Outcomes of Primary and Secondary Prophylaxis.

Journal: Journal of vascular and interventional radiology : JVIR

Published: May 21, 2025

Safety and Effectiveness of Transarterial Chemoembolization for Caudate Lobe Hepatocellular Carcinoma: Long-Term Clinical Outcomes.

Safety and Effectiveness of Transarterial Chemoembolization for Caudate Lobe Hepatocellular Carcinoma: Long-Term Clinical Outcomes.

Journal: Journal of vascular and interventional radiology : JVIR

Published: March 25, 2025

Long-term outcomes of plug-assisted retrograde transvenous obliteration (PARTO) for refractory hepatic encephalopathy.

Long-term outcomes of plug-assisted retrograde transvenous obliteration (PARTO) for refractory hepatic encephalopathy.

Journal: European radiology

Published: February 24, 2025

Model Predicting Survival in Intermediate-Stage HCC Patients Reclassified for TACE Based on the 2022 BCLC Criteria.

Model Predicting Survival in Intermediate-Stage HCC Patients Reclassified for TACE Based on the 2022 BCLC Criteria.

Journal: Cancers

Published: February 08, 2025

Showing 1-12 of 56

Last Updated: 09/26/2026